UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A proof-of-concept study of the effect of a novel H3 -receptor antagonist in allergen-induced nasal congestion

Journal of allergy and clinical immunology, 2013-10, Vol.132 (4), p.838-846.e6

2013

Volltextzugriff (PDF)

Filgotinib in Active Noninfectious Uveitis: The HUMBOLDT Randomized Clinical Trial

JAMA ophthalmology, 2024-09, Vol.142 (9), p.789

2024

Volltextzugriff (PDF)

Evaluation of the Effects of Meal Type and Acid‐Reducing Agents on the Pharmacokinetics of Cilofexor, a Selective Nonsteroidal Farnesoid X Receptor Agonist

Clinical pharmacology in drug development, 2024-06, Vol.13 (6), p.677-687

2024

Volltextzugriff (PDF)

Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab′)2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels

Critical care medicine, 2004-11, Vol.32 (11), p.2173-2182

2004

Volltextzugriff (PDF)

Cilofexor in Patients With Compensated Cirrhosis Due to Primary Sclerosing Cholangitis: An Open-Label Phase 1B Study

Clinical and translational gastroenterology, 2024-08, Vol.15 (8), p.e00744

2024

Volltextzugriff (PDF)

Serologic extracellular matrix remodeling markers are related to fibrosis stage and prognosis in a phase 2b trial of simtuzumab in patients with primary sclerosing cholangitis

Hepatology communications, 2024-07, Vol.8 (7)

2024

Volltextzugriff (PDF)

A multicenter, open-label, prospective, randomized, dose-ranging pharmacokinetic study of the anti-TNF-α antibody afelimomab in patients with sepsis syndrome

Intensive care medicine, 2001-07, Vol.27 (7), p.1169-1178

2001

Volltextzugriff (PDF)

A proof-of-concept study of the effect of a novel H sub(3)-receptor antagonist in allergen-induced nasal congestion

Journal of allergy and clinical immunology, 2013-10, Vol.132 (4), p.838-846.e6

2013

Volltextzugriff (PDF)

A multicenter, open-label, prospective, randomized, dose-ranging pharmacokinetic study of the anti-TNF-[alpha] antibody afelimomab in patients with sepsis syndrome

Intensive care medicine, 2001-07, Vol.27 (7), p.1169

2001

Volltextzugriff (PDF)

Immunology and ocular manifestations of giant cell arteritis

Ocular immunology and inflammation, 1997, Vol.5 (2), p.141-146

1997

Volltextzugriff (PDF)

Adequacy of Early Empiric Antibiotic Treatment and Survival in Severe Sepsis: Experience from the MONARCS Trial

Clinical infectious diseases, 2004-01, Vol.38 (2), p.284-288

2004

Volltextzugriff (PDF)

Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study

The Lancet (British edition), 2018-06, Vol.391 (10136), p.2213-2224

2018

Volltextzugriff (PDF)

Filgotinib decreases both vertebral body and posterolateral spine inflammation in ankylosing spondylitis: results from the TORTUGA trial

Rheumatology (Oxford, England), 2022-05, Vol.61 (6), p.2388-2397

2022

Volltextzugriff (PDF)

Impact of filgotinib on sacroiliac joint magnetic resonance imaging structural lesions at 12 weeks in patients with active ankylosing spondylitis (TORTUGA trial)

Rheumatology (Oxford, England), 2022-05, Vol.61 (5), p.2063-2071

2022

Volltextzugriff (PDF)

FRI-360 - Elevated JAG1-NOTCH Signaling is Associated with Fibrosis Stages in Patients with PSC

Journal of hepatology, 2023-06, Vol.78, p.S423-S425

2023

Volltextzugriff (PDF)

Elevated JAG1-NOTCH Signaling is Associated with Fibrosis Stages in Patients with PSC

Journal of hepatology, 2023-06, Vol.78, p.S423-S425

2023

Volltextzugriff (PDF)

Safety and Efficacy of Poseltinib, Bruton’s Tyrosine Kinase Inhibitor, in Patients With Rheumatoid Arthritis: A Randomized, Double-blind, Placebo-controlled, 2-part Phase II Study

Journal of rheumatology, 2021-07, Vol.48 (7), p.969-976

2021

Volltextzugriff (PDF)

A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of cilofexor in patients with non-cirrhotic primary sclerosing cholangitis (PRIMIS)

Journal of hepatology, 2023-06, Vol.78, p.S12-S13

2023

Volltextzugriff (PDF)

LBO-03 - A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of cilofexor in patients with non-cirrhotic primary sclerosing cholangitis (PRIMIS)

Journal of hepatology, 2023-06, Vol.78, p.S12-S13

2023

Volltextzugriff (PDF)

Toreforant, an orally active histamine H 4 -receptor antagonist, in patients with active rheumatoid arthritis despite methotrexate: mechanism of action results from a phase 2, multicenter, randomized, double-blind, placebo-controlled synovial biopsy study

Inflammation research, 2019-04, Vol.68 (4), p.261

2019

Volltextzugriff (PDF)

Toreforant, an orally active histamine H4-receptor antagonist, in patients with active rheumatoid arthritis despite methotrexate: mechanism of action results from a phase 2, multicenter, randomized, double-blind, placebo-controlled synovial biopsy study

Inflammation research, 2019-04, Vol.68 (4), p.261-274

2019

Volltextzugriff (PDF)

1 – 21 von 21

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(21)
Mit Volltextzugriff
(19)

Publikationsform

Artikel
(21)

Sprache

Englisch
(21)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

A proof-of-concept study of the effect of a novel H3 -receptor antagonist in allergen-induced nasal congestion

Filgotinib in Active Noninfectious Uveitis: The HUMBOLDT Randomized Clinical Trial

Evaluation of the Effects of Meal Type and Acid‐Reducing Agents on the Pharmacokinetics of Cilofexor, a Selective Nonsteroidal Farnesoid X Receptor Agonist

Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab′)2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels

Cilofexor in Patients With Compensated Cirrhosis Due to Primary Sclerosing Cholangitis: An Open-Label Phase 1B Study

Serologic extracellular matrix remodeling markers are related to fibrosis stage and prognosis in a phase 2b trial of simtuzumab in patients with primary sclerosing cholangitis

A multicenter, open-label, prospective, randomized, dose-ranging pharmacokinetic study of the anti-TNF-α antibody afelimomab in patients with sepsis syndrome

A proof-of-concept study of the effect of a novel H sub(3)-receptor antagonist in allergen-induced nasal congestion

A multicenter, open-label, prospective, randomized, dose-ranging pharmacokinetic study of the anti-TNF-[alpha] antibody afelimomab in patients with sepsis syndrome

Immunology and ocular manifestations of giant cell arteritis

Adequacy of Early Empiric Antibiotic Treatment and Survival in Severe Sepsis: Experience from the MONARCS Trial

Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study

Filgotinib decreases both vertebral body and posterolateral spine inflammation in ankylosing spondylitis: results from the TORTUGA trial

Impact of filgotinib on sacroiliac joint magnetic resonance imaging structural lesions at 12 weeks in patients with active ankylosing spondylitis (TORTUGA trial)

FRI-360 - Elevated JAG1-NOTCH Signaling is Associated with Fibrosis Stages in Patients with PSC

Elevated JAG1-NOTCH Signaling is Associated with Fibrosis Stages in Patients with PSC

Safety and Efficacy of Poseltinib, Bruton’s Tyrosine Kinase Inhibitor, in Patients With Rheumatoid Arthritis: A Randomized, Double-blind, Placebo-controlled, 2-part Phase II Study

A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of cilofexor in patients with non-cirrhotic primary sclerosing cholangitis (PRIMIS)

LBO-03 - A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of cilofexor in patients with non-cirrhotic primary sclerosing cholangitis (PRIMIS)

Toreforant, an orally active histamine H 4 -receptor antagonist, in patients with active rheumatoid arthritis despite methotrexate: mechanism of action results from a phase 2, multicenter, randomized, double-blind, placebo-controlled synovial biopsy study

Toreforant, an orally active histamine H4-receptor antagonist, in patients with active rheumatoid arthritis despite methotrexate: mechanism of action results from a phase 2, multicenter, randomized, double-blind, placebo-controlled synovial biopsy study

Suchergebnisse filtern